Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Medical Center Groningen, Groningen, the Netherlands.
Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.
Our aim was to examine the clinicopathologic characteristics and survival of ovarian, tubal, and peritoneal (further denoted "adnexal") cancer in BRCA1 compared with BRCA2 carriers.
A consecutive series of adnexal cancers in BRCA1/2 mutation carriers diagnosed in 1980 to 2010 at the University Medical Center Groningen was analyzed.
We evaluated 55 BRCA1- and 16 BRCA2-related adnexal cancers, consisting of 51 ovarian, 13 tubal, and 7 peritoneal cancers. Peritoneal cancer was restricted to BRCA1 carriers. Ovarian and tubal cancer was equally present in both carrier groups. Median age at diagnosis was younger in BRCA1 compared with BRCA2 carriers (50 vs 54 years; P = 0.03). No other clinicopathologic differences were found. Regarding survival, a nonsignificant trend was noted for BRCA2 carriers to have fewer relapses, a longer time to first relapse, and a longer disease-free and overall survival.
Except for age at diagnosis and prevalence of peritoneal cancer, no significant clinicopathologic differences were found between BRCA1- versus BRCA2-associated adnexal cancer. On survival, it might be suggested that BRCA2 carriers have a more favorable outcome than BRCA1 carriers, marked by fewer relapses, a longer time to first relapse, and a longer disease-free and overall survival.
本研究旨在比较 BRCA1 与 BRCA2 携带者中卵巢、输卵管和腹膜（进一步表示为“附件”）癌的临床病理特征和生存情况。
对 1980 年至 2010 年在格罗宁根大学医学中心诊断的 BRCA1/2 突变携带者中连续系列的附件癌进行了分析。
我们评估了 55 例 BRCA1 相关和 16 例 BRCA2 相关的附件癌，包括 51 例卵巢癌、13 例输卵管癌和 7 例腹膜癌。腹膜癌仅限于 BRCA1 携带者。卵巢癌和输卵管癌在两个携带者组中同样存在。BRCA1 携带者的诊断年龄中位数低于 BRCA2 携带者（50 岁比 54 岁；P=0.03）。未发现其他临床病理差异。关于生存情况，BRCA2 携带者的复发次数较少、首次复发时间较长、无病生存期和总生存期较长，这一趋势具有统计学意义。
除了诊断时的年龄和腹膜癌的患病率外，BRCA1 与 BRCA2 相关附件癌之间没有显著的临床病理差异。在生存方面，BRCA2 携带者的复发次数较少、首次复发时间较长、无病生存期和总生存期较长，这表明 BRCA2 携带者的预后可能优于 BRCA1 携带者。
